Clinical Trial Update: Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 [Phase 1, Phase 2]

View source ↗

Summary

Extension study update for IMO-8400 in Waldenström's macroglobulinemia following completing a prior study; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• IMO-8400

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Waldenstrom's Macroglobulinemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-11-13